Wells Fargo Initiates Coverage on AnaptysBio Stock with Bullish Outlook
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market. Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB). The company's shares closed the week almost 8% higher in price, according to data compiled by S&P Global Market Intelligence, largely on the strength of a research note published by a high-profile and influential bank.
Doing well by Wells Fargo
- On Thursday, Wells Fargo initiated coverage of AnaptysBio stock with an overweight recommendation at a target price of $56 per share.
A potential double dose
- Analysts believe AnaptysBio's rosnilimab could rival peresolimab from Eli Lilly, potentially leading to significant gains if successful in clinical trials.
Before you buy stock in AnaptysBio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AnaptysBio wasn’t one of them. See which stocks made the list and why.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.